Loading...
Market
First Company to Announce New Huntington's Treatment Strategy by End of 2025?
2
Resolution / Starting Odds
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Announcements from pharmaceutical companies
Story
New Research Reveals Genetic Insights into Huntington's Disease, a Fatal Brain Disorder, and Potential for Improved Treatments
Jan 16, 2025, 05:32 PM
Recent research has provided new insights into Huntington's disease, a hereditary disorder characterized by the degeneration of nerve cells in the brain. A study revealed that an inherited genetic mutation may drive the disease, reshaping the understanding of its biological mechanisms. This research highlights the potential for new therapeutic strategies aimed at slowing or stopping the progression of the disease. Notably, findings indicate that the genetic basis of Huntington's disease involves a 'ticking DNA clock,' where CAG repeats in the DNA slowly expand throughout a person's life. These developments may lead to improved treatment options for individuals affected by this fatal condition, which often strikes in the prime of life.
View original story
Similar markets
Yes • 50%
No • 50%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Pfizer • 25%
Moderna • 25%
Other • 25%
No • 50%
Yes • 50%
LEQEMBI leads market • 25%
Other • 25%
No clear market leader • 25%
Competitor drug leads market • 25%
AstraZeneca • 25%
Moderna • 25%
Pfizer • 25%
Other • 25%
Merck • 25%
Other • 25%
Johnson & Johnson • 25%
Pfizer • 25%
